Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.8K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fibrous dysplasia: clinical and pathologic characteristics, surgical approaches, and outcomes in a large Italian cohort.

Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology·2026
Same author

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
Same author

Drug-loaded biomorphic scaffolds for tissue regeneration and targeted antitumor therapy in bone metastasis models.

Biomaterials advances·2026
Same author

Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].

Critical reviews in oncology/hematology·2026
Same author

Imaging of Fibrous Dysplasia: A Comprehensive In-Depth Analysis of Monostotic, Polyostotic, Syndromic Forms, and Bone Sarcoma Development.

Journal of imaging·2026
Same author

Circulating IGF2BP3 enables risk stratification and predicts treatment response in Ewing sarcoma.

Scientific reports·2026

Related Experiment Video

Updated: Apr 17, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.8K

MDM2 and CDK4 expression in periosteal osteosarcoma.

Alberto Righi1, Marco Gambarotti1, Stefania Benini1

  • 1Pathology Department, Rizzoli Institute, Bologna, Italy 40136.

Human Pathology
|February 15, 2015
PubMed
Summary
This summary is machine-generated.

Mouse double minute 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) are rarely expressed in periosteal osteosarcoma. These markers are not central to cancer progression and cannot differentiate this subtype from others.

Keywords:
BoneCDK4ImmunohistochemistryMDM2Perisoteal osteosarcoma

More Related Videos

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

1.7K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.5K

Related Experiment Videos

Last Updated: Apr 17, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.8K
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
02:35

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

1.7K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.5K

Area of Science:

  • Oncology
  • Molecular Pathology
  • Skeletal Neoplasms

Background:

  • Periosteal osteosarcoma is an intermediate-grade malignant neoplasm.
  • Limited data exist on mouse double minute 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) expression in this subtype.

Purpose of the Study:

  • To evaluate MDM2 and CDK4 expression and MDM2 amplification in periosteal osteosarcoma.
  • To determine if these markers are involved in cancer development and progression.
  • To assess their diagnostic utility in differentiating periosteal osteosarcoma.

Main Methods:

  • Retrospective analysis of 27 periosteal osteosarcoma cases.
  • Immunohistochemistry for MDM2 and CDK4 protein expression.
  • Fluorescence in situ hybridization (FISH) for MDM2 gene amplification.

Main Results:

  • 96.3% of cases were negative for MDM2 protein.
  • No MDM2 gene amplification was detected.
  • CDK4 expression was negative in all cases.
  • MDM2 and CDK4 are rarely expressed in periosteal osteosarcoma.

Conclusions:

  • MDM2 and CDK4 are not central to periosteal osteosarcoma development or progression.
  • These markers lack diagnostic value for differentiating periosteal osteosarcoma from other subtypes.